Current treatment of type 1 diabetes (T1D) consists only of exogenous insulins and Symlin, with Lantus as the patient-share leader in the United States. Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated T1D. However, differences exist in choice of branded insulin, choice of regimen, and order in which brands and/or regimens are attempted. In addition, the launch of biosimilar insulins is having a profound effect on the T1D therapy market, and we are witnessing mixed physician attitudes toward this new treatment option.
Geographies: United States
Real World Data: Longitudinal patient-level claims data analysis
Key Drugs Covered: Lantus, Levemir, Toujeo, Apidra, NovoLog, Fiasp, Humalog, Tresiba, Admelog, Basaglar
Key analysis provided:
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.